SELE and Miyoshi myopathy: As recombinant E-selectin is not able to protect the Heca452 enriched cells from bortezomib in vitro25, the current hypothesis is that in vivo, E-selectin promotes homing and retention of the Heca452 enriched MM cells in the BM where they are protected from chemotherapeutic drugs such as bortezomib.